These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 20306843)

  • 1. Care of patients undergoing intra-vitreal therapy.
    Watkinson S; Scott E
    Nurs Stand; 2010 Feb 24-Mar 2; 24(25):42-7. PubMed ID: 20306843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ranibizumab therapy for neovascular age-related macular degeneration.
    Folk JC; Stone EM
    N Engl J Med; 2010 Oct; 363(17):1648-55. PubMed ID: 20961248
    [No Abstract]   [Full Text] [Related]  

  • 3. Vitreomacular traction in a case of exudative age-related macular degeneration resistant to anti-VEGF therapy.
    Shah SU; Haller JA
    Acta Ophthalmol; 2012 Nov; 90(7):e569-70. PubMed ID: 22429537
    [No Abstract]   [Full Text] [Related]  

  • 4. Randomized study of bevacizumab vs ranibizumab for age-related macular degeneration: inappropriate conclusions.
    Messori A; Fadda V; Trippoli S
    Am J Ophthalmol; 2010 May; 149(5):867; author reply 867. PubMed ID: 20399931
    [No Abstract]   [Full Text] [Related]  

  • 5. [Experience of Lucentis use in patients with wet age-related macular degeneration].
    Dolgova IG; Malishevskaia TN; Rybina IM
    Vestn Oftalmol; 2012; 128(5):26-31. PubMed ID: 23210344
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined intravitreal pharmacosurgery in patients with occult choroidal neovascularization secondary to wet age-related macular degeneration.
    Koss MJ; Scholtz S; Haeussler-Sinangin Y; Singh P; Koch FH
    Ophthalmologica; 2010; 224(2):72-8. PubMed ID: 19707030
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bevacizumab vs ranibizumab for age-related macular degeneration: early results of a prospective double-masked, randomized clinical trial.
    Donahue SP; Recchia F; Sternberg P
    Am J Ophthalmol; 2010 Aug; 150(2):287; author reply 287. PubMed ID: 20670740
    [No Abstract]   [Full Text] [Related]  

  • 8. Reflux of drug during intra-vitreal anti-VEGF therapies.
    Usman Saeed M; Batra R; Qureshi F; Clark D
    Semin Ophthalmol; 2011 Nov; 26(6):357-60. PubMed ID: 22044333
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of older people with dry and wet age-related macular degeneration.
    Watkinson S
    Nurs Older People; 2010 Jun; 22(5):21-6. PubMed ID: 20617714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The importance of informed consent in patients with wet age-related macular degeneration considering intravitreal anti-vascular endothelial growth factor treatments.
    McLaughlin S; Lockington D; Mansfield D
    Scott Med J; 2012 Feb; 57(1):48-9. PubMed ID: 22408217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bevacizumab vs ranibizumab for age-related macular degeneration: early results of a prospective double-masked, randomized clinical trial.
    Subramanian ML; Ness S; Abedi G; Ahmed E; Daly M; Feinberg E; Bhatia S; Patel P; Nguyen M; Houranieh A
    Am J Ophthalmol; 2009 Dec; 148(6):875-82.e1. PubMed ID: 19800611
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retreatment with anti-vascular endothelial growth factor therapy based on changes in visual acuity after initial stabilization of neovascular age-related macular degeneration: 3-year follow-up results.
    Dunavoelgyi R; Sacu S; Eibenberger K; Palkovits S; Leydolt C; Pruente C; Schmidt-Erfurth U
    Retina; 2012 Sep; 32(8):1471-9. PubMed ID: 22414958
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Controversies in the treatment of wet age-related macular degeneration.
    Moreno SF; Paloma JB
    Am J Ophthalmol; 2008 May; 145(5):937; author reply 938. PubMed ID: 18435977
    [No Abstract]   [Full Text] [Related]  

  • 14. [New drug treatment for age-related macular degeneration].
    Stefánsson E; la Cour M; Helgadóttir G; Sigurdsson H; Jónasson F
    Laeknabladid; 2007 Apr; 93(4):299-301. PubMed ID: 17460341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Anti-VEGF therapy of neovascular age-related macular degeneration: therapeutic strategies status December 2012].
    Pauleikhoff D; Bertram B; Holz FG; Kirchhof B; Bartz-Schmidt U; Bornfeld N; Bresgen M; Eter N; Friedrichs W; Heimann H; Helbig H; Hörauf H; Kampik A; Lemmen KD; Roider J; Ziemssen F
    Klin Monbl Augenheilkd; 2013 Feb; 230(2):170-7. PubMed ID: 23430681
    [No Abstract]   [Full Text] [Related]  

  • 16. Visual outcomes and growth factor changes of two dosages of intravitreal bevacizumab for neovascular age-related macular degeneration: a randomized, controlled trial.
    Lai TY; Liu DT; Chan KP; Luk FO; Pang CP; Lam DS
    Retina; 2009 Oct; 29(9):1218-26. PubMed ID: 19934816
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab.
    Bakall B; Folk JC; Boldt HC; Sohn EH; Stone EM; Russell SR; Mahajan VB
    Am J Ophthalmol; 2013 Jul; 156(1):15-22.e1. PubMed ID: 23706500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Switching anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration.
    Schachat AP
    Am J Ophthalmol; 2013 Jul; 156(1):1-2.e1. PubMed ID: 23791369
    [No Abstract]   [Full Text] [Related]  

  • 19. Tachyphylaxis and bevacizumab.
    Ziemssen F; Neuhann IM; Voelker M
    Ophthalmology; 2009 Aug; 116(8):1591-2; author reply 1592-3. PubMed ID: 19651319
    [No Abstract]   [Full Text] [Related]  

  • 20. Tachyphylaxis and bevacizumab.
    Avgikos KN; Horgan SE; Sivaraj RR; Hu K
    Ophthalmology; 2009 Sep; 116(9):1831-2; author reply 1832. PubMed ID: 19729101
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.